Transcript Slide 1
European Association for Vision and Eye Research – Crete, Oct 5-8, 2011 Ophthalmic surgical clinic “Rascheskoff”, Kazan, Russia Drs. O.Ziyatdinova, L.Safiullina Ranibizumab for the Treatment of Exudative Age-Related Macular Degeneration Associated With Retinal Pigment Epithelial Detachment Financial Disclosure Dr Olesya Ziyatdinova (the presenter) has no financial interest in the subject matter of this topic Purpose To evaluate the efficacy of intravitreal ranibizumab in eyes with exudative age-related macular degeneration associated with retinal pigment epithelial detachment. Materials and methods The study included 15 patients (15 eyes) with exudative age-related macular degeneration associated with retinal pigment epithelial detachment. 10 eyes without foveal involvement 5 eyes with foveal involvement Duration of disease: from 3 to 12 months Observation time: 12 months Number of injections: from 1 to 6 times Technique Injection of 0,5 mg (0,05ml) of ranibizumab into vitreous body Lower quadrant at a distance of 4 mm from limbus, needle 30G Slow introduction IOP control and instillation of antibiotics after operation Technique Criteria of efficacy Visual acuity (BCVA, UCVA) OCT Ophthalmoscopy Results Average BCVA increased from 20/100 to 20/50 and the average retinal thickness decreased from 367 +/-111 mkm to 281+/- 104 mkm in 8 eyes (53,4%) without foveal involvement. Results BCVA remained stable in 5 eyes (33,3%) but there was a decrease only in 2 eyes (13,3%) with foveal involvement. 3 eyes (20%) showed disease stabilization after 1st injection 12 eyes (80%) required re-injection of the ranibizumab for 1-2 months OCT dynamics Before 1 month later 3 months later Conclusions Intravitreal ranibizumab was effective in improving or stabilizing vision of patients with exudative age-related macular degeneration associated with retinal pigment epithelial detachment. The functional results were better in eyes without foveal involvement with retinal pigment epithelial detachment. Visual acuity and OCT data are reliable criteria for evaluating the efficacy of intravitreal ranibizumab in eyes with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.